Genentech's glyco-engineered antibody to succeed Rituxan

Nat Biotechnol. 2014 Jan;32(1):6-7. doi: 10.1038/nbt0114-6b.
No abstract available

Publication types

  • News

MeSH terms

  • Antibodies / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Drug Industry
  • Humans
  • Lymphoma, T-Cell / drug therapy*
  • Metabolic Engineering*
  • Rituximab
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab